| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
* Division of Therapeutic Proteins, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892;
Department of Biochemistry and Molecular Biology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103;
Protein Structure Section, Macromolecular Crystallography Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702;
Ludwig Institute for Cancer Research, and the Experimental Medicine Unit, Christian de Duve Institute for Cellular Pathology, Université de Louvain, Brussels, Belgium
The receptor for IL-26 (AK155), a cytokine of the IL-10 family, has not previously been defined. We demonstrate that the active receptor complex for IL-26 is a heterodimer composed of two receptor proteins: IL-20R1 and IL-10R2. Signaling through the IL-26R results in activation of STAT1 and STAT3 which can be blocked by neutralizing Abs against IL-20R1 or IL-10R2. IL-10R2 is broadly expressed on a wide variety of tissues, whereas only a limited number of tissues express IL-20R1. Therefore, the ability to respond to IL-26 is restricted by the expression of IL-20R1. IL-10, IL-19, IL-20, IL-22, and IL-24 fail to signal through the combination of IL-10R2 and IL-20R1 proteins, demonstrating that this receptor combination is unique and specific for IL-26.
This article has been cited by other articles:
|
|
 |
|
  S. M. Sa, P. A. Valdez, J. Wu, K. Jung, F. Zhong, L. Hall, I. Kasman, J. Winer, Z. Modrusan, D. M. Danilenko, et al. The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis J. Immunol., February 15, 2007; 178(4): 2229 - 2240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lasfar, A. Lewis-Antes, S. V. Smirnov, S. Anantha, W. Abushahba, B. Tian, K. Reuhl, H. Dickensheets, F. Sheikh, R. P. Donnelly, et al. Characterization of the Mouse IFN-{lambda} Ligand-Receptor System: IFN-{lambda}s Exhibit Antitumor Activity against B16 Melanoma. Cancer Res., April 15, 2006; 66(8): 4468 - 4477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Poindexter, E. T. Walch, S. Chada, and E. A. Grimm Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells J. Leukoc. Biol., September 1, 2005; 78(3): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hor, H. Pirzer, L. Dumoutier, F. Bauer, S. Wittmann, H. Sticht, J.-C. Renauld, R. de Waal Malefyt, and H. Fickenscher The T-cell Lymphokine Interleukin-26 Targets Epithelial Cells through the Interleukin-20 Receptor 1 and Interleukin-10 Receptor 2 Chains J. Biol. Chem., August 6, 2004; 279(32): 33343 - 33351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Donnelly, F. Sheikh, S. V. Kotenko, and H. Dickensheets The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain J. Leukoc. Biol., August 1, 2004; 76(2): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dumoutier, A. Tounsi, T. Michiels, C. Sommereyns, S. V. Kotenko, and J.-C. Renauld Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-{lambda}1: SIMILARITIES WITH TYPE I INTERFERON SIGNALING J. Biol. Chem., July 30, 2004; 279(31): 32269 - 32274. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
